​

Lantheus (LNTH) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Lantheus Revenue Highlights

Latest Revenue (Y)

$1.53B

Latest Revenue (Q)

$391.11M

Main Segment (Y)

Product

Main Geography (Y)

US Segment

Lantheus Revenue by Period

Lantheus Revenue by Year

DateRevenueChange
2024-12-31$1.53B18.32%
2023-12-31$1.30B38.65%
2022-12-31$935.06M119.91%
2021-12-31$425.21M25.28%
2020-12-31$339.41M-2.28%
2019-12-31$347.34M1.15%
2018-12-31$343.37M3.62%
2017-12-31$331.38M9.78%
2016-12-31$301.85M2.86%
2015-12-31$293.46M-2.70%
2014-12-31$301.60M6.32%
2013-12-31$283.67M-1.54%
2012-12-31$288.11M-19.14%
2011-12-31$356.29M-

Lantheus generated $1.53B in revenue during NA 2024, up 18.32% compared to the previous quarter, and up 441.62% compared to the same period a year ago.

Lantheus Revenue by Quarter

DateRevenueChange
2024-12-31$391.11M3.27%
2024-09-30$378.73M-3.90%
2024-06-30$394.09M6.52%
2024-03-31$369.98M4.51%
2023-12-31$354.00M10.64%
2023-09-30$319.95M-0.55%
2023-06-30$321.70M6.95%
2023-03-31$300.78M14.29%
2022-12-31$263.17M9.98%
2022-09-30$239.29M6.96%
2022-06-30$223.72M7.11%
2022-03-31$208.88M61.22%
2021-12-31$129.56M26.93%
2021-09-30$102.07M1.00%
2021-06-30$101.06M9.25%
2021-03-31$92.51M-1.75%
2020-12-31$94.15M6.33%
2020-09-30$88.54M34.14%
2020-06-30$66.01M-27.22%
2020-03-31$90.70M1.52%
2019-12-31$89.35M4.16%
2019-09-30$85.78M0.08%
2019-06-30$85.70M-0.93%
2019-03-31$86.51M0.28%
2018-12-31$86.27M-2.96%
2018-09-30$88.90M3.89%
2018-06-30$85.57M3.56%
2018-03-31$82.63M1.71%
2017-12-31$81.24M1.63%
2017-09-30$79.94M-10.01%
2017-06-30$88.84M9.19%
2017-03-31$81.36M9.43%
2016-12-31$74.35M1.76%
2016-09-30$73.06M-6.29%
2016-06-30$77.97M1.95%
2016-03-31$76.47M7.41%
2015-12-31$71.20M-3.94%
2015-09-30$74.12M1.10%
2015-06-30$73.31M-2.02%
2015-03-31$74.82M-2.79%
2014-12-31$76.97M1.70%
2014-09-30$75.68M0.09%
2014-06-30$75.61M3.10%
2014-03-31$73.34M2.33%
2013-12-31$71.67M1.82%
2013-09-30$70.39M-0.31%
2013-06-30$70.60M-0.59%
2013-03-31$71.02M-

Lantheus generated $391.11M in revenue during Q4 2024, up 3.27% compared to the previous quarter, and up 122.24% compared to the same period a year ago.

Lantheus Revenue Breakdown

Lantheus Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
DEFINITY$317.79M$279.77M$244.99M$232.76M-
License and Royalty Revenues$9.13M$33.36M$48.02M$24.85M-
Other Precision Diagnostics$24.23M$22.98M$22.82M$26.97M-
Other Radiopharmaceutical Oncology$384.00K$3.13M$4.10M$5.47M-
PYLARIFY$1.06B$851.30M$527.40M$43.41M-
Product$1.52B$1.26B---
Radiopharmaceutical Oncology$1.06B$854.43M$531.51M$48.89M-
Strategic Partnerships And Other$38.18M$51.88M$46.87M$25.30M-
Techne Lite$95.49M$87.37M$88.86M$91.29M-
Total Precision Diagnostics$437.51M$390.12M$356.68M$351.02M-
Product Revenue, Net--$887.04M$400.36M-
International Segment----$44.61M
US Segment----$294.80M

Lantheus's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (33.41%), Radiopharmaceutical Oncology (23.19%), PYLARIFY (23.18%), Total Precision Diagnostics (9.59%), DEFINITY (6.96%), Techne Lite (2.09%), Strategic Partnerships And Other (0.84%), Other Precision Diagnostics (0.53%), License and Royalty Revenues (0.20%), and Other Radiopharmaceutical Oncology (0.01%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Jun 24Mar 24Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20
Total Precision Diagnostics$104.36M$117.46M$103.73M$112.11M$104.21M$96.35M$97.58M$95.62M$94.37M$89.01M$87.11M$86.20M$87.04M$87.88M$90.36M$85.75M----
DEFINITY$79.21M$86.16M$76.97M$78.10M$76.56M$67.34M$70.53M$68.82M$63.62M$60.74M$62.31M$58.33M$59.31M$57.64M$59.84M$55.97M----
License and Royalty Revenues$5.85M$3.00M$4.13M$1.33M$662.00K$438.00K$7.62M$8.53M$7.29M$5.93M$5.94M$28.87M$6.76M$5.39M$7.50M$5.19M----
Other Precision Diagnostics$5.44M$6.19M$6.28M$5.83M$5.93M$5.74M$5.45M$5.81M$6.02M$6.17M$5.36M$5.26M$5.68M$7.56M$6.74M$6.98M----
PYLARIFY$257.65M$265.95M$259.76M$273.25M$258.87M$215.43M$210.52M$195.47M$160.64M$143.75M$130.23M$92.78M--------
Product$366.92M$388.11M$374.60M$392.76M$369.31M$319.51M$314.08M$292.26M$233.37M$217.78M$180.01M$96.68M$93.56M$87.32M------
Radiopharmaceutical Oncology$257.65M$265.95M$259.76M$273.25M$259.25M$216.28M$211.34M$196.19M$161.56M$144.68M$131.16M$94.10M$35.68M$8.89M$2.81M$1.50M----
Strategic Partnerships And Other$10.75M$7.70M$15.25M$8.72M$6.51M$7.32M$12.78M$8.98M$7.24M$5.60M$5.45M$28.58M$6.84M$5.30M$7.90M$5.25M----
Techne Lite$19.71M$25.11M$20.48M$28.19M$21.71M$23.27M$21.59M$20.99M$24.73M$22.09M$19.44M$22.61M$22.04M$22.68M$23.77M$22.80M----
Other Radiopharmaceutical Oncology---$384.00K$848.00K$818.00K$717.00K$919.00K$928.00K$928.00K$1.33M---------
International Segment----------------$12.97M$11.07M$8.61M$11.96M
US Segment----------------$81.18M$77.47M$57.40M$78.75M

Lantheus's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (33.13%), PYLARIFY (23.26%), Radiopharmaceutical Oncology (23.26%), Total Precision Diagnostics (9.42%), DEFINITY (7.15%), Techne Lite (1.78%), Strategic Partnerships And Other (0.97%), License and Royalty Revenues (0.53%), and Other Precision Diagnostics (0.49%).

Lantheus Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 20Dec 19Dec 18
US Segment$294.80M$72.53M-
Worldwide-$347.34M-
UNITED STATES--$288.58M
All Other--$54.79M

Lantheus's latest annual revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Quarterly Revenue by Country

CountryDec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18Mar 18
US Segment$81.18M$77.47M$57.40M$19.36M$78.72M$74.65M$75.19M$75.43M$72.75M$70.25M$74.09M$71.49M

Lantheus's latest quarterly revenue breakdown by geography, as of Dec 20: US Segment (100.00%).

Lantheus Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RDYDr. Reddy's Laboratories$279.16B-
NBIXNeurocrine Biosciences$2.36B$572.60M
ALKSAlkermes$1.56B$306.51M
LNTHLantheus$1.53B$391.11M
AMPHAmphastar Pharmaceuticals$712.81M$186.98M
PCRXPacira BioSciences$700.97M$187.25M
COLLCollegium Pharmaceutical$631.45M$181.95M
ANIPANI Pharmaceuticals$614.38M$190.57M
IRWDIronwood Pharmaceuticals$351.41M$41.14M
DVAXDynavax$277.25M$72.03M
AVDLAvadel Pharmaceuticals$169.12M$50.41M
AQSTAquestive Therapeutics$57.56M$8.72M
DERMJourney Medical$56.13M$14.86M

LNTH Revenue FAQ

What is Lantheus’s yearly revenue?

Lantheus's yearly revenue for 2024 was $1.53B, representing an increase of 18.32% compared to 2023. The company's yearly revenue for 2023 was $1.3B, representing an increase of 38.65% compared to 2022. LNTH's yearly revenue for 2022 was $935.06M, representing an increase of 119.91% compared to 2021.

What is Lantheus’s quarterly revenue?

Lantheus's quarterly revenue for Q4 2024 was $391.11M, a 3.27% increase from the previous quarter (Q3 2024), and a 10.48% increase year-over-year (Q4 2023). The company's quarterly revenue for Q3 2024 was $378.73M, a -3.90% decrease from the previous quarter (Q2 2024), and a 18.37% increase year-over-year (Q3 2023). LNTH's quarterly revenue for Q2 2024 was $394.09M, a 6.52% increase from the previous quarter (Q1 2024), and a 22.50% increase year-over-year (Q2 2023).

What is Lantheus’s revenue growth rate?

Lantheus's revenue growth rate for the last 3 years (2022-2024) was 64.04%, and for the last 5 years (2020-2024) was 351.93%.

What are Lantheus’s revenue streams?

Lantheus's revenue streams in c 24 are DEFINITY, License and Royalty Revenues, Other Precision Diagnostics, Other Radiopharmaceutical Oncology, PYLARIFY, Product, Radiopharmaceutical Oncology, Strategic Partnerships And Other, Techne Lite, and Total Precision Diagnostics. DEFINITY generated $317.79M in revenue, accounting 6.96% of the company's total revenue, up 13.59% year-over-year. License and Royalty Revenues generated $9.13M in revenue, accounting 0.20% of the company's total revenue, down -72.64% year-over-year. Other Precision Diagnostics generated $24.23M in revenue, accounting 0.53% of the company's total revenue, up 5.44% year-over-year. Other Radiopharmaceutical Oncology generated $384K in revenue, accounting 0.01% of the company's total revenue, down -87.73% year-over-year. PYLARIFY generated $1.06B in revenue, accounting 23.18% of the company's total revenue, up 24.26% year-over-year. Product generated $1.52B in revenue, accounting 33.41% of the company's total revenue, up 20.72% year-over-year. Radiopharmaceutical Oncology generated $1.06B in revenue, accounting 23.19% of the company's total revenue, up 23.85% year-over-year. Strategic Partnerships And Other generated $38.18M in revenue, accounting 0.84% of the company's total revenue, down -26.40% year-over-year. Techne Lite generated $95.49M in revenue, accounting 2.09% of the company's total revenue, up 9.29% year-over-year. Total Precision Diagnostics generated $437.51M in revenue, accounting 9.59% of the company's total revenue, up 12.15% year-over-year.

What is Lantheus’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Lantheus was Product. This segment made a revenue of $1.52B, representing 33.41% of the company's total revenue.